In a mouse model of non-metastatic ovarian cancer cachexia, where elevated RANKL levels cause muscle atrophy, the administration of anti-RANKL has been shown to reduce muscle mass loss and dysfunction (Pin et al., 2022). The gene discussed is TNFSF11; the disease is ovarian carcinoma.